22:35 , Jul 19, 2019 |  BioCentury  |  Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

A draft FDA guidance for heart failure endpoints could spark investment and accelerate development of cardiovascular therapies. But companies still don’t have a clear sense of when and whether they’ll need to gather mortality data...
16:29 , Sep 21, 2018 |  BC Week In Review  |  Company News

Novo's R&D restructuring adds to innovation push

Four new R&D centers fueled by a dedicated business development unit and increased investment in machine learning and AI form the basis of an R&D restructuring announced by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) on...
20:53 , Sep 18, 2018 |  BC Extra  |  Company News

Novo's R&D restructuring adds to innovation push

Four new R&D centers fueled by a dedicated business development unit and increased investment in machine learning and AI form the basis of an R&D restructuring announced by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) on...
22:45 , Sep 6, 2018 |  BC Extra  |  Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
19:28 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Venrock leads Corvidia's $60M series B

Corvidia Therapeutics Inc. (Waltham, Mass.) raised $60 million on April 25 in a series B round led by Venrock. Fellow new investors Andera (formerly Edmond de Rothschild Investment Partners), Cormorant Asset Management, HBM Healthcare Investments,...
20:43 , Apr 25, 2018 |  BC Extra  |  Financial News

Venrock leads Corvidia's $60M series B

Corvidia Therapeutics Inc. (Waltham, Mass.) raised $60 million in a series B round led by Venrock. Fellow new investors Andera (formerly Edmond de Rothschild Investment Partners), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care...
01:06 , Feb 8, 2018 |  BC Extra  |  Company News

Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business...
17:01 , Jan 12, 2018 |  BC Week In Review  |  Company News

Pfizer creates ITEN target discovery network with academia

Pfizer Inc. (NYSE:PFE) announced its Innovative Target Exploration Network (ITEN), an early stage partnering model to identify research projects with the potential to deliver new therapeutic targets and mechanisms of action for future discovery efforts...
19:26 , Dec 22, 2017 |  BC Week In Review  |  Financial News

Madrigal raises $143.8M in follow-on

On Dec. 18, cardio-metabolic disease company Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) raised $143.8 million through the sale of 1.7 million shares at $83 in a follow-on underwritten by Goldman Sachs, Evercore ISI, JMP Securities, Roth Capital...
16:30 , Aug 18, 2017 |  BC Week In Review  |  Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...